Overview

A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Status:
Terminated

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether ARC-520 in combination with entecavir is effective in the treatment of patients with chronic HBV Infection.

Phase:

Phase 2

Details

Lead Sponsor:

Arrowhead Pharmaceuticals

Collaborator:

ICON Clinical Research

Treatments:

Chlorpheniramine
Entecavir